788 related articles for article (PubMed ID: 22196207)
1. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.
Pfaller MA
Am J Med; 2012 Jan; 125(1 Suppl):S3-13. PubMed ID: 22196207
[TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
3. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
4. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Alexander BD; Johnson MD; Pfeiffer CD; Jiménez-Ortigosa C; Catania J; Booker R; Castanheira M; Messer SA; Perlin DS; Pfaller MA
Clin Infect Dis; 2013 Jun; 56(12):1724-32. PubMed ID: 23487382
[TBL] [Abstract][Full Text] [Related]
5. Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong
Schell WA; Jones AM; Garvey EP; Hoekstra WJ; Schotzinger RJ; Alexander BD
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956419
[TBL] [Abstract][Full Text] [Related]
6. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
Beyda ND; John J; Kilic A; Alam MJ; Lasco TM; Garey KW
Clin Infect Dis; 2014 Sep; 59(6):819-25. PubMed ID: 24879785
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species.
Astvad KM; Perlin DS; Johansen HK; Jensen RH; Arendrup MC
Antimicrob Agents Chemother; 2013 Jan; 57(1):177-82. PubMed ID: 23089746
[TBL] [Abstract][Full Text] [Related]
8. Clinical perspectives on echinocandin resistance among Candida species.
Shields RK; Nguyen MH; Clancy CJ
Curr Opin Infect Dis; 2015 Dec; 28(6):514-22. PubMed ID: 26524326
[TBL] [Abstract][Full Text] [Related]
9. Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.
Shields RK; Nguyen MH; Press EG; Cumbie R; Driscoll E; Pasculle AW; Clancy CJ
Antimicrob Agents Chemother; 2015 Dec; 59(12):7465-70. PubMed ID: 26392494
[TBL] [Abstract][Full Text] [Related]
10. Echinocandin Resistance in Candida.
Perlin DS
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S612-7. PubMed ID: 26567278
[TBL] [Abstract][Full Text] [Related]
11. Resistance to echinocandin antifungal agents in the United Kingdom in clinical isolates of Candida glabrata: Fifteen years of interpretation and assessment.
Fraser M; Borman AM; Thorn R; Lawrance LM
Med Mycol; 2020 Feb; 58(2):219-226. PubMed ID: 31111912
[TBL] [Abstract][Full Text] [Related]
12. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.
Beyda ND; Lewis RE; Garey KW
Ann Pharmacother; 2012; 46(7-8):1086-96. PubMed ID: 22811350
[TBL] [Abstract][Full Text] [Related]
13. Absence of Azole or Echinocandin Resistance in Candida glabrata Isolates in India despite Background Prevalence of Strains with Defects in the DNA Mismatch Repair Pathway.
Singh A; Healey KR; Yadav P; Upadhyaya G; Sachdeva N; Sarma S; Kumar A; Tarai B; Perlin DS; Chowdhary A
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610199
[No Abstract] [Full Text] [Related]
14.
Jiménez-Ortigosa C; Perez WB; Angulo D; Borroto-Esoda K; Perlin DS
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630180
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
16. Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria.
Klotz U; Schmidt D; Willinger B; Steinmann E; Buer J; Rath PM; Steinmann J
Mycoses; 2016 May; 59(5):312-8. PubMed ID: 26806376
[TBL] [Abstract][Full Text] [Related]
17. Antifungal resistance does not necessarily affect Candida glabrata fitness.
Borghi E; Andreoni S; Cirasola D; Ricucci V; Sciota R; Morace G
J Chemother; 2014 Feb; 26(1):32-6. PubMed ID: 24091025
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
[TBL] [Abstract][Full Text] [Related]
19. Anidulafungin Susceptibility Testing of Candida glabrata Isolates from Blood Cultures by the MALDI Biotyper Antibiotic (Antifungal) Susceptibility Test Rapid Assay.
Vatanshenassan M; Arastehfar A; Boekhout T; Berman J; Lass-Flörl C; Sparbier K; Kostrzewa M
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285227
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?
Espinel-Ingroff A; Cantón E
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():3-9. PubMed ID: 21420570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
